No connection

Search Results

AHCO vs GENB

AHCO
AdaptHealth Corp.
BEARISH
Price
$10.60
Market Cap
$1.44B
Sector
Healthcare
AI Confidence
85%
GENB
Generate Biomedicines, Inc.
BEARISH
Price
$11.53
Market Cap
$1.47B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
AHCO
--
GENB
--
Forward P/E
AHCO
8.52
GENB
-5.44
P/B Ratio
AHCO
0.92
GENB
-0.94
P/S Ratio
AHCO
0.44
GENB
46.08
EV/EBITDA
AHCO
5.53
GENB
--

Profitability

Gross Margin
AHCO
20.89%
GENB
0.0%
Operating Margin
AHCO
6.2%
GENB
-737.04%
Profit Margin
AHCO
-2.18%
GENB
0.0%
ROE
AHCO
-4.25%
GENB
-81.72%
ROA
AHCO
2.9%
GENB
-34.63%

Growth

Revenue Growth
AHCO
-1.2%
GENB
--
Earnings Growth
AHCO
--
GENB
--

Financial Health

Debt/Equity
AHCO
1.25
GENB
--
Current Ratio
AHCO
1.02
GENB
2.85
Quick Ratio
AHCO
0.71
GENB
2.69

Dividends

Dividend Yield
AHCO
--
GENB
--
Payout Ratio
AHCO
0.0%
GENB
0.0%

AI Verdict

AHCO BEARISH

AHCO's Advanced Deterministic Scorecard reveals significant financial distress signals: a Piotroski F-Score of 2/9 indicates weak operational and financial health, with negative ROE (-4.25%) and declining revenue (-1.20% YoY). The absence of an Altman Z-Score raises concern about bankruptcy risk, while the Graham Number and intrinsic value are unavailable, suggesting no reliable fundamental valuation anchor. Despite a modest 1Y return of +10.2%, the stock has underperformed over 3Y (-20.2%) and 5Y (-72.3%), reflecting deep structural issues. Analysts recommend 'buy' with a target of $12.88, but this optimism is not supported by deteriorating fundamentals or consistent earnings beats.

Strengths
Positive operating margin (6.20%) indicates some operational efficiency despite losses
Price/Sales of 0.44 suggests potential undervaluation relative to revenue
Recent Q/Q EPS growth of +68.8% shows possible short-term recovery momentum
Risks
Piotroski F-Score of 2/9 signals severe financial weakness and poor profitability trends
Negative profit margin (-2.18%) and declining revenue (-1.20% YoY) indicate deteriorating business fundamentals
Debt/Equity ratio of 1.25 is elevated, especially with a current ratio of 1.02 and quick ratio of 0.71, indicating liquidity strain
GENB BEARISH

GENB presents a high-risk speculative profile with a Piotroski F-Score of 4/9, indicating only marginal financial stability. The company exhibits severe fundamental distress, characterized by a negative Price-to-Book ratio (-0.94) and an extreme Price-to-Sales ratio of 46.08, suggesting the market is pricing in immense future growth that is not yet supported by revenue. While the current ratio of 2.85 provides a short-term liquidity cushion, the operating margin of -737.04% and a 0/100 technical trend signal strong downward momentum. There is a stark divergence between the 'Strong Buy' analyst consensus and the actual deterministic financial health and price action.

Strengths
Strong short-term liquidity with a Current Ratio of 2.85
Healthy Quick Ratio of 2.69 indicating low reliance on inventory
Strong analyst backing with a target price of $25.00
Risks
Extreme valuation with a Price/Sales ratio of 46.08
Negative equity as evidenced by the Price/Book ratio of -0.94
Severe operational losses with an operating margin of -737.04%

Compare Another Pair

AHCO vs GENB: Head-to-Head Comparison

This page compares AdaptHealth Corp. (AHCO) and Generate Biomedicines, Inc. (GENB) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile